In a presentation at Pharmaceutical Management Science Association’s Fall Symposium 2022, Indegene highlighted one of the most challenging areas in pharmaceutical forecasting - the oncology forecast. The presentation delved deeper into some of the complexities that oncology forecasters face and highlighted what they can do to navigate through and how they can benefit from dynamic patient- and patient-flow-based models.
Lung Adenocarcinoma Market 2023: Epidemiology, Industry Trends, Size, Share A...frankmorgan27
The growing incidence of tobacco consumption, such as cigarettes, pipes, and cigars, known to damage lung tissue and cultivate an environment conducive to cancer cell development, is primarily propelling the lung adenocarcinoma market.
Intratumoral Cancer Therapies Market 2023: Epidemiology, Industry Trends, Siz...frankmorgan27
The elevating prevalence of cancer and the inflating need for therapies that can deliver drugs directly to the tumor site, enabling the targeted treatment, are primarily stimulating the intratumoral cancer therapies market.
The Science of Launching and Achieving Growth in Oncologyaccenture
We have conducted research to understand how oncology companies are responding to New science, more treatment choices and changing economics. Visit https://accntu.re/2Jn72wq to learn our key takeaways for launching and achieving growth in oncology.
Malignant Pleural Mesothelioma Market 2023: Epidemiology, Industry Trends, Si...frankmorgan27
The elevating cases of exposure to asbestos fibers, which become lodged in the lining of the abdomen, lungs, or heart, and cause irritation and inflammation, are primarily augmenting the malignant pleural mesothelioma market.
di Pier Giuseppe Pelicci, MD-PhD, Istituto Europeo di Oncologia IEO, Università degli Studi di Milano.
Slide per l'intervento tenuto in Fondazione Giannino Bassetti in occasione del primo incontro del ciclo "La medicina di precisione", primo progetto dalla convenzione tra Università di Pavia e Fondazione Bassetti.
12 marzo 2018
Risk Based Monitoring in Clinical trials_Aishwarya Janjale.pptxClinosolIndia
Risk-Based Monitoring (RBM) in clinical trials represents a departure from traditional, one-size-fits-all monitoring approaches. This innovative strategy tailors monitoring activities to the specific risks associated with a trial, optimizing resource utilization and enhancing data quality. This article explores the key principles, benefits, and challenges of RBM, illustrating its transformative impact on the landscape of clinical trial oversight.
Key Principles:
Risk Identification and Assessment:
RBM begins with a comprehensive assessment of potential risks to data integrity, patient safety, and study endpoints. These risks are identified based on factors such as study complexity, patient population, and investigational product characteristics.
A brief presentation of the market space created by the ongoing ebola epidemic, and projected cost estimates for scale up production vaccine introduction of an ebola vaccine.
Lung Adenocarcinoma Market 2023: Epidemiology, Industry Trends, Size, Share A...frankmorgan27
The growing incidence of tobacco consumption, such as cigarettes, pipes, and cigars, known to damage lung tissue and cultivate an environment conducive to cancer cell development, is primarily propelling the lung adenocarcinoma market.
Intratumoral Cancer Therapies Market 2023: Epidemiology, Industry Trends, Siz...frankmorgan27
The elevating prevalence of cancer and the inflating need for therapies that can deliver drugs directly to the tumor site, enabling the targeted treatment, are primarily stimulating the intratumoral cancer therapies market.
The Science of Launching and Achieving Growth in Oncologyaccenture
We have conducted research to understand how oncology companies are responding to New science, more treatment choices and changing economics. Visit https://accntu.re/2Jn72wq to learn our key takeaways for launching and achieving growth in oncology.
Malignant Pleural Mesothelioma Market 2023: Epidemiology, Industry Trends, Si...frankmorgan27
The elevating cases of exposure to asbestos fibers, which become lodged in the lining of the abdomen, lungs, or heart, and cause irritation and inflammation, are primarily augmenting the malignant pleural mesothelioma market.
di Pier Giuseppe Pelicci, MD-PhD, Istituto Europeo di Oncologia IEO, Università degli Studi di Milano.
Slide per l'intervento tenuto in Fondazione Giannino Bassetti in occasione del primo incontro del ciclo "La medicina di precisione", primo progetto dalla convenzione tra Università di Pavia e Fondazione Bassetti.
12 marzo 2018
Risk Based Monitoring in Clinical trials_Aishwarya Janjale.pptxClinosolIndia
Risk-Based Monitoring (RBM) in clinical trials represents a departure from traditional, one-size-fits-all monitoring approaches. This innovative strategy tailors monitoring activities to the specific risks associated with a trial, optimizing resource utilization and enhancing data quality. This article explores the key principles, benefits, and challenges of RBM, illustrating its transformative impact on the landscape of clinical trial oversight.
Key Principles:
Risk Identification and Assessment:
RBM begins with a comprehensive assessment of potential risks to data integrity, patient safety, and study endpoints. These risks are identified based on factors such as study complexity, patient population, and investigational product characteristics.
A brief presentation of the market space created by the ongoing ebola epidemic, and projected cost estimates for scale up production vaccine introduction of an ebola vaccine.
The medical sector's innovations drive ongoing change in the healthcare technology sector. From MRI scans and X-rays to robotic surgery and virtual reality, the healthcare industry is undergoing a significant digital shift. To get a report in detail, contact us at - info@insights10.com
March 02, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
Colorectal Cancer Market 2023: Epidemiology, Industry Trends, Size, Share And...frankmorgan27
The increasing occurrences of polyps and inflammatory bowel conditions like ulcerative colitis or Crohn’s disease are primarily propelling the colorectal cancer market.
A compliant CER should support strong clinical evidence that your device achieves its intended purpose without exposing users and patients to risk. The CER must be based on clinical data, which may include clinical data from existing literature, clinical experience, clinical trials, or any combination of the three.
You are required to prepare and submit a clinical evaluation report with your technical file as part of the CE Marking/conformity assessment process. However, approach the CER as a standalone document.
Clinical evaluation report cer in a more stringent regulatory- Pepgra HealthcarePEPGRA Healthcare
European regulatory framework has established rules that govern the development, manufacturing, and marketing of medical devices in the European market. Both European and non-European medical device manufacturer’s fall under the purview of the regulatory framework, which is established to
provide condence to the clinicians and the patients that the medical devices and the implantable devices used in the region have been validated for their potential benets and certied as safe for usage.
Real world clinical medical data. Corporate presentation of Ad Scientiam which is a startup specialized in real life data acquisition during clinical trials.
Learn more at : www.adscientiam.com
Non-Small Cell Lung Cancer Pipeline Insight | Non-Small Cell Lung Cancer Pipe...Dr. B.K. Agrawal
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Managed entry Agreements for orphan medicines, DOlon LTD, ECRD 2016richsear
Investigation of managed entry agreements
to address uncertainty around orphan drug
pricing and reimbursement decisions, poster session, Dolon LTD, ECRD 2016
Global lung cancer vaccine market & pipeline insight 2015KuicK Research
“Global Lung Cancer Vaccine Market & Pipeline Insight 2015” Report Highlights:
Introduction to Lung Cancer Vaccine
Global Lung Cancer Vaccine Market Analysis
Global Lung Cancer Vaccine Pipeline by Company & Phase
Global Lung Cancer Vaccine Pipeline: 29 Vaccines
Majority Lung Cancer Vaccines in Phase-II: 8 Vaccines
Marketed Lung Cancer Vaccines: 3 ( BV NSCLC 001, Mycidac-C™ & Vaxira®)
Personalized Cancer Vaccines: Progress & Possibilities
Lung Cancer Vaccine Mechanism
Vulvar Cancer Market 2023: Epidemiology, Industry Trends, Size, Share And For...frankmorgan27
Vulvar cancer is a medical condition associated with abnormal cell growth on the vulva, the external part of the female genitalia, which encompasses the clitoris, labia majora and minora, vaginal opening, and the skin in its vicinity.
Leiomyosarcoma Market 2023: Epidemiology, Industry Trends, Size, Share And Fo...frankmorgan27
The elevating cases of certain genetic conditions, such as renal cell cancer (HLRCC) syndrome and hereditary leiomyomatosis, which is characterized by the development of leiomyomas, are primarily augmenting the leiomyosarcoma market.
Cell-Based Assay Market 2022-2027: Size, Share, Trends, Analysis & Research ...IMARC Group
According to the latest report by IMARC Group, that the global cell-based assay market size reached US$ 18.9 Billion in 2021. Cell-based assay or cellular assay is an analytical method to determine the concentration of a substance by observing its effects on living organisms (in vivo) or tissues (in vitro). It provides a closer representation of the real-life model, which helps to verify the biological activity of drugs and determine whether the antibodies produced by the patient are neutralizing the drug.
We offer safety-proof patient experiences with effective monitoring, analysis, reporting, and risk mitigation of adverse event signals across the product life cycle. Indegene's pharmacovigilance solution offer a digitally enabled solution to help you reduce your total cost of ownership while ensuring persistent regulatory compliance.
Our priority is to empower life sciences organizations with compliant and high-value patient support solutions that put them on the trajectory to patient experience success. From innovative affordability constructs and tech-enabled hub-point solutions to state-of-the-art adherence-promoting solutions, our diverse range of offerings helps simplify patient lives by delivering holistic support across their journeys.
More Related Content
Similar to Navigating the complexity of forecasting in the oncology market
The medical sector's innovations drive ongoing change in the healthcare technology sector. From MRI scans and X-rays to robotic surgery and virtual reality, the healthcare industry is undergoing a significant digital shift. To get a report in detail, contact us at - info@insights10.com
March 02, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
Colorectal Cancer Market 2023: Epidemiology, Industry Trends, Size, Share And...frankmorgan27
The increasing occurrences of polyps and inflammatory bowel conditions like ulcerative colitis or Crohn’s disease are primarily propelling the colorectal cancer market.
A compliant CER should support strong clinical evidence that your device achieves its intended purpose without exposing users and patients to risk. The CER must be based on clinical data, which may include clinical data from existing literature, clinical experience, clinical trials, or any combination of the three.
You are required to prepare and submit a clinical evaluation report with your technical file as part of the CE Marking/conformity assessment process. However, approach the CER as a standalone document.
Clinical evaluation report cer in a more stringent regulatory- Pepgra HealthcarePEPGRA Healthcare
European regulatory framework has established rules that govern the development, manufacturing, and marketing of medical devices in the European market. Both European and non-European medical device manufacturer’s fall under the purview of the regulatory framework, which is established to
provide condence to the clinicians and the patients that the medical devices and the implantable devices used in the region have been validated for their potential benets and certied as safe for usage.
Real world clinical medical data. Corporate presentation of Ad Scientiam which is a startup specialized in real life data acquisition during clinical trials.
Learn more at : www.adscientiam.com
Non-Small Cell Lung Cancer Pipeline Insight | Non-Small Cell Lung Cancer Pipe...Dr. B.K. Agrawal
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Managed entry Agreements for orphan medicines, DOlon LTD, ECRD 2016richsear
Investigation of managed entry agreements
to address uncertainty around orphan drug
pricing and reimbursement decisions, poster session, Dolon LTD, ECRD 2016
Global lung cancer vaccine market & pipeline insight 2015KuicK Research
“Global Lung Cancer Vaccine Market & Pipeline Insight 2015” Report Highlights:
Introduction to Lung Cancer Vaccine
Global Lung Cancer Vaccine Market Analysis
Global Lung Cancer Vaccine Pipeline by Company & Phase
Global Lung Cancer Vaccine Pipeline: 29 Vaccines
Majority Lung Cancer Vaccines in Phase-II: 8 Vaccines
Marketed Lung Cancer Vaccines: 3 ( BV NSCLC 001, Mycidac-C™ & Vaxira®)
Personalized Cancer Vaccines: Progress & Possibilities
Lung Cancer Vaccine Mechanism
Vulvar Cancer Market 2023: Epidemiology, Industry Trends, Size, Share And For...frankmorgan27
Vulvar cancer is a medical condition associated with abnormal cell growth on the vulva, the external part of the female genitalia, which encompasses the clitoris, labia majora and minora, vaginal opening, and the skin in its vicinity.
Leiomyosarcoma Market 2023: Epidemiology, Industry Trends, Size, Share And Fo...frankmorgan27
The elevating cases of certain genetic conditions, such as renal cell cancer (HLRCC) syndrome and hereditary leiomyomatosis, which is characterized by the development of leiomyomas, are primarily augmenting the leiomyosarcoma market.
Cell-Based Assay Market 2022-2027: Size, Share, Trends, Analysis & Research ...IMARC Group
According to the latest report by IMARC Group, that the global cell-based assay market size reached US$ 18.9 Billion in 2021. Cell-based assay or cellular assay is an analytical method to determine the concentration of a substance by observing its effects on living organisms (in vivo) or tissues (in vitro). It provides a closer representation of the real-life model, which helps to verify the biological activity of drugs and determine whether the antibodies produced by the patient are neutralizing the drug.
Similar to Navigating the complexity of forecasting in the oncology market (20)
We offer safety-proof patient experiences with effective monitoring, analysis, reporting, and risk mitigation of adverse event signals across the product life cycle. Indegene's pharmacovigilance solution offer a digitally enabled solution to help you reduce your total cost of ownership while ensuring persistent regulatory compliance.
Our priority is to empower life sciences organizations with compliant and high-value patient support solutions that put them on the trajectory to patient experience success. From innovative affordability constructs and tech-enabled hub-point solutions to state-of-the-art adherence-promoting solutions, our diverse range of offerings helps simplify patient lives by delivering holistic support across their journeys.
At Indegene, with our digital-first approach, we bring agility and innovation to your launch strategy. We enable optimization of channels, content mix and foster continuous learning by adopting an agile operating model that supports cross-functional collaboration and enables launch teams to rapidly create campaigns to address shifting customer needs. With our AI-driven launch model, from strategy to execution, we help you achieve true ‘Launch Excellence’.
Our priority is to empower life sciences organizations with compliant and high-value patient support solutions that put them on the trajectory to patient experience success. From innovative affordability constructs and tech-enabled hub-point solutions to state-of-the-art adherence-promoting solutions, our diverse range of offerings helps simplify patient lives by delivering holistic support across their journeys.
At Indegene, with our digital-first approach, we bring agility and innovation to your launch strategy. We enable optimization of channels, content mix and foster continuous learning by adopting an agile operating model that supports cross-functional collaboration and enables launch teams to rapidly create campaigns to address shifting customer needs. With our AI-driven launch model, from strategy to execution, we help you achieve true ‘Launch Excellence’.
Moving to digital labeling: Journey to achieving Desired OutcomesIndegene
A step wise guide to move towards Digital Labeling. This presentation identifies the challenges and changes in the life sciences industry related to labeling and its impact. The future demands of labeling, including greater use of digital solutions, advances in language standards, increased use of mobile technologies, and a focus on simplicity and accessibility, are also discussed. The presentation concludes by emphasizing the need for companies to make their labeling operations future-ready and outlines a five-step framework for process redesign to improve labeling processes.
Navigating the complexity of forecasting in the oncology marketIndegene
In a presentation at Pharmaceutical Management Science Association’s Fall Symposium 2022, Indegene highlighted one of the most challenging areas in pharmaceutical forecasting - the oncology forecast. The presentation delved deeper into some of the complexities that oncology forecasters face and highlighted what they can do to navigate through and how they can benefit from dynamic patient- and patient-flow-based models.
Enabling your commercial operations to be future ready. A solution to augment measurement frameworks and optimize business and operational dimensions with data, insights, and recommendations to drive efficiencies in commercial operations.
Grow revenue, elevate customer experience and augment teams with a modern GTM model using Digital first solutions that use deep HCP insights to grow revenue through an outcome-based model.
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It’s what drives our team and our purpose to enable healthcare organizations to be future ready.
Empowering medical device organizations across the product value chain. Make the most of your data to enhance your competitiveness and elevate customer experience.
Communicate scientific information effectively, improve regulatory compliance and manage safety operations efficiently. Medical operations need to be future ready by adopting technology to accelerate and scale medical outcomes.
Technology-led solutions that span across the clinical R&D lifecycle including study startup, conduct and closeout, driving clinical development programs to faster decisions, and predictable success.
Development and Co-Commercialization for Emerging Biotech organizationsIndegene
Develop, launch and market your product with an experienced partner. Innovative, technology-led, purpose-built, end-to-end and individual development and commercialization solutions from Phase 2 clinical trials to Loss Of Exclusivity (LOE) for a more effective, sustained, and higher peak revenue.
At Indegene, each of us plays a role in contributing to equity, diversity, and inclusion. The culture we portray at the company is a direct outcome of our attitude to work, our dedication to making things happen, the way we collaborate, and how we share our thoughts and perspectives.
We are a technology-led healthcare solutions provider. We combine deep industry expertise with fit-for-purpose technology in an agile and scalable operating model. Many of the leading global healthcare organizations rely on us to deliver effective and efficient clinical, medical, and commercial outcomes every day. From strategy to execution, we enable healthcare organizations be future ready.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.